152 related articles for article (PubMed ID: 18493999)
1. Changes in morphology of in situ forming PLGA implant prepared by different polymer molecular weight and its effect on release behavior.
Astaneh R; Erfan M; Moghimi H; Mobedi H
J Pharm Sci; 2009 Jan; 98(1):135-45. PubMed ID: 18493999
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive characterization of the effect of varying PLGA molecular weight blends on in situ forming implant behavior using ultrasound imaging.
Solorio L; Olear AM; Hamilton JI; Patel RB; Beiswenger AC; Wallace JE; Zhou H; Exner AA
Theranostics; 2012; 2(11):1064-77. PubMed ID: 23227123
[TBL] [Abstract][Full Text] [Related]
3. Estradiol loaded PLGA nanoparticles for oral administration: effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo.
Mittal G; Sahana DK; Bhardwaj V; Ravi Kumar MN
J Control Release; 2007 May; 119(1):77-85. PubMed ID: 17349712
[TBL] [Abstract][Full Text] [Related]
4. Preparation of DHAQ-loaded mPEG-PLGA-mPEG nanoparticles and evaluation of drug release behaviors in vitro/in vivo.
Duan Y; Sun X; Gong T; Wang Q; Zhang Z
J Mater Sci Mater Med; 2006 Jun; 17(6):509-16. PubMed ID: 16691348
[TBL] [Abstract][Full Text] [Related]
5. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
[TBL] [Abstract][Full Text] [Related]
6. An investigation into the influence of drug lipophilicity on the in vivo absorption profiles from subcutaneous microspheres and in situ forming depots.
Deadman CM; Kellaway IW; Yasin M; Dickinson PA; Murdan S
J Control Release; 2007 Sep; 122(1):79-85. PubMed ID: 17638603
[TBL] [Abstract][Full Text] [Related]
7. The influence of the use of viscosifying agents as dispersion media on the drug release properties from PLGA nanoparticles.
Dillen K; Weyenberg W; Vandervoort J; Ludwig A
Eur J Pharm Biopharm; 2004 Nov; 58(3):539-49. PubMed ID: 15451528
[TBL] [Abstract][Full Text] [Related]
8. Influence of formulation composition and process on the characteristics and in vitro release from PLGA-based sustained release injectables.
Meeus J; Scurr DJ; Appeltans B; Amssoms K; Annaert P; Davies MC; Roberts CJ; Van den Mooter G
Eur J Pharm Biopharm; 2015 Feb; 90():22-9. PubMed ID: 25448071
[TBL] [Abstract][Full Text] [Related]
9. A potential approach for decreasing the burst effect of protein from PLGA microspheres.
Fu K; Harrell R; Zinski K; Um C; Jaklenec A; Frazier J; Lotan N; Burke P; Klibanov AM; Langer R
J Pharm Sci; 2003 Aug; 92(8):1582-91. PubMed ID: 12884245
[TBL] [Abstract][Full Text] [Related]
10. Potential applications of PLGA film-implants in modulating in vitro drugs release.
Dorta MJ; Santoveña A; Llabrés M; Fariña JB
Int J Pharm; 2002 Nov; 248(1-2):149-56. PubMed ID: 12429469
[TBL] [Abstract][Full Text] [Related]
11. PLGA/mesoporous silica hybrid structure for controlled drug release.
Xue JM; Shi M
J Control Release; 2004 Aug; 98(2):209-17. PubMed ID: 15262413
[TBL] [Abstract][Full Text] [Related]
12. Elevated temperature accelerated release testing of PLGA microspheres.
Zolnik BS; Leary PE; Burgess DJ
J Control Release; 2006 May; 112(3):293-300. PubMed ID: 16644055
[TBL] [Abstract][Full Text] [Related]
13. Biodegradable microparticles for sustained release of a new GnRH antagonist--part I: Screening commercial PLGA and formulation technologies.
Schwach G; Oudry N; Delhomme S; Lück M; Lindner H; Gurny R
Eur J Pharm Biopharm; 2003 Nov; 56(3):327-36. PubMed ID: 14602174
[TBL] [Abstract][Full Text] [Related]
14. Biodegradable poly(D, L-lactide-co-glycolide) (PLGA) microspheres for sustained release of risperidone: Zero-order release formulation.
Su ZX; Shi YN; Teng LS; Li X; Wang LX; Meng QF; Teng LR; Li YX
Pharm Dev Technol; 2011 Aug; 16(4):377-84. PubMed ID: 20370594
[TBL] [Abstract][Full Text] [Related]
15. Molecular weight distribution changes during degradation and release of PLGA nanoparticles containing epirubicin HCl.
Birnbaum DT; Brannon-Peppas L
J Biomater Sci Polym Ed; 2003; 14(1):87-102. PubMed ID: 12635772
[TBL] [Abstract][Full Text] [Related]
16. Properties of poly(lactic-co-glycolic acid) nanospheres containing protease inhibitors: camostat mesilate and nafamostat mesilate.
Yin J; Noda Y; Yotsuyanagi T
Int J Pharm; 2006 May; 314(1):46-55. PubMed ID: 16551494
[TBL] [Abstract][Full Text] [Related]
17. Extended release microparticle-in-gel formulation of octreotide: Effect of polymer type on acylation of peptide during in vitro release.
Vaishya RD; Mandal A; Patel S; Mitra AK
Int J Pharm; 2015 Dec; 496(2):676-88. PubMed ID: 26561725
[TBL] [Abstract][Full Text] [Related]
18. Nanoparticulate drug carriers based on hybrid poly(D,L-lactide-co-glycolide)-dendron structures.
Costantino L; Gandolfi F; Bossy-Nobs L; Tosi G; Gurny R; Rivasi F; Vandelli MA; Forni F
Biomaterials; 2006 Sep; 27(26):4635-45. PubMed ID: 16716395
[TBL] [Abstract][Full Text] [Related]
19. Chemical imaging of drug eluting coatings: combining surface analysis and confocal Raman microscopy.
Belu A; Mahoney C; Wormuth K
J Control Release; 2008 Mar; 126(2):111-21. PubMed ID: 18201791
[TBL] [Abstract][Full Text] [Related]
20. Bupivacaine-loaded biodegradable poly(lactic-co-glycolic) acid microspheres I. Optimization of the drug incorporation into the polymer matrix and modelling of drug release.
Zhang H; Lu Y; Zhang G; Gao S; Sun D; Zhong Y
Int J Pharm; 2008 Mar; 351(1-2):244-9. PubMed ID: 18024022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
